Search Results - "Livasy, Chad A"

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study by Carey, Lisa A, Perou, Charles M, Livasy, Chad A, Dressler, Lynn G, Cowan, David, Conway, Kathleen, Karaca, Gamze, Troester, Melissa A, Tse, Chiu Kit, Edmiston, Sharon, Deming, Sandra L, Geradts, Joseph, Cheang, Maggie C. U, Nielsen, Torsten O, Moorman, Patricia G, Earp, H. Shelton, Millikan, Robert C

“…CONTEXT Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2…”
Get full text

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma by Livasy, Chad A, Karaca, Gamze, Nanda, Rita, Tretiakova, Maria S, Olopade, Olufunmilayo I, Moore, Dominic T, Perou, Charles M

“…Microarray profiling of invasive breast carcinomas has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, HER2…”
Get full text

Identification of a basal-like subtype of breast ductal carcinoma in situ by Livasy, Chad A., MD, Perou, Charles M., PhD, Karaca, Gamze, MSc, Cowan, David W., BS, Maia, Diane, MD, Jackson, Susan, MPA, Tse, Chiu-Kit, MSPH, Nyante, Sarah, MSPH, Millikan, Robert C., PhD, DVM

“…Summary Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The…”
Get full text

Molecular Characterization of Human Breast Tumor Vascular Cells by Bhati, Rajendra, Patterson, Cam, Livasy, Chad A, Fan, Cheng, Ketelsen, David, Hu, Zhiyuan, Reynolds, Evangeline, Tanner, Catherine, Moore, Dominic T, Gabrielli, Franco, Perou, Charles M, Klauber-DeMore, Nancy

“…A detailed understanding of the assortment of genes that are expressed in breast tumor vessels is needed to facilitate the development of novel, molecularly…”
Get full text

FAK overexpression and p53 mutations are highly correlated in human breast cancer by Golubovskaya, Vita M., Conway‐Dorsey, Kathleen, Edmiston, Sharon N., Tse, Chiu‐Kit, Lark, Amy A., Livasy, Chad A., Moore, Dominic, Millikan, Robert C., Cance, William G.

“…Focal adhesion kinase (FAK) is overexpressed in a number of tumors, including breast cancer. Another marker of breast cancer tumorigenesis is the tumor…”
Get full text

Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts by Sambade, Maria J., Ph.D, Kimple, Randall J., M.D., Ph.D, Camp, J. Terese, B.S, Peters, Eldon, B.S, Livasy, Chad A., M.D, Sartor, Carolyn I., M.D, Shields, Janiel M., Ph.D

“…Purpose To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer…”
Get full text

Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination by Calhoun, Benjamin C., MD, PhD, Chambers, Karinn, MD, Flippo-Morton, Teresa, MD, Livasy, Chad A., MD, Armstrong, Edward J., BS, Symanowski, James T., PhD, Sarantou, Terry, MD, Greene, Frederick L., MD, White, Richard L., MD

“…Summary At Carolinas Medical Center, before 2008, axillary sentinel lymph nodes (SLNs) from breast cancer patients were evaluated with a single hematoxylin and…”
Get full text

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1 by Norris, Eric J., Jones, Wendell D., Surleac, Marius D., Petrescu, Andrei J., Destephanis, Darla, Zhang, Qing, Hamadeh, Issam, Kneisl, Jeffrey S., Livasy, Chad A., Ganapathi, Ram N., Tait, David L., Ganapathi, Mahrukh K.

“…Neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene encoding neurofibromin, which negatively regulates Ras signaling. NF1 patients have an…”
Get full text

Cosmetic Outcomes for Accelerated Partial Breast Irradiation Before Surgical Excision of Early-Stage Breast Cancer Using Single-Dose Intraoperative Radiotherapy by Kimple, Randall J., M.D., Ph.D, Klauber-DeMore, Nancy, M.D, Kuzmiak, Cherie M., D.O, Pavic, Dag, M.D, Lian, Jun, Ph.D, Livasy, Chad A., M.D, Esler, Laura, B.A, Moore, Dominic T., M.P.H, Sartor, Carolyn I., M.D, Ollila, David W., M.D

“…Purpose Determine cosmetic outcome and toxicity profile of intraoperative radiation delivered before tumor excision for patients with early-stage breast…”
Get full text

Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy by Sandhu, Rupninder, Parker, Joel S, Jones, Wendell D, Livasy, Chad A, Coleman, William B

“…Basal-like breast cancers represent approximately 15%-20% of all breast carcinomas, are aggressive, have variable responses to chemotherapy, and associated…”
Get full text

Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy by Elder, Erin A., Livasy, Chad A., Donahue, Erin E., Neelands, Brittany, Patrick, Alicia, Needham, Mckenzie, Sarantou, Terry, Hadzikadic-Gusic, Lejla, Heeke, Arielle L., White, Richard L.

“…Background The residual cancer burden class informs survival outcomes after neoadjuvant chemotherapy. We evaluated the prognostic ability of the RCB for…”
Get full text

ASO Visual Abstract: Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy by Elder, Erin A., Livasy, Chad A., Donahue, Erin E., Neelands, Brittany, Patrick, Alicia, Needham, Mckenzie, Sarantou, Terry, Hadzikadic-Gusic, Lejla, Heeke, Arielle L., White, Richard L.

Get full text

ASO Visual Abstract: Does Residual Cancer Burden Predict Local Recurrence after Neoadjuvant Chemotherapy? by Pestana, Christine V., Livasy, Chad A, Donahue, Erin E, Neelands, Brittany, Tan, Antoinette R., Sarantou, Terry, Hadzikadic-Gusic, Lejla, White, Richard L.

Get full text

Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer by SANDHU, RUPNINDER, RIVENBARK, ASHLEY G, MACKLER, RANDI M, LIVASY, CHAD A, COLEMAN, WILLIAM B

“…Basal-like breast cancers frequently express aberrant DNA hypermethylation associated with concurrent silencing of specific genes secondary to DNMT3b…”
Get full text

Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies by Calhoun, Benjamin C, Sobel, Amy, White, Richard L, Gromet, Matt, Flippo, Teresa, Sarantou, Terry, Livasy, Chad A

“…Flat epithelial atypia of the breast commonly co-exists with atypical ductal hyperplasia, lobular neoplasia, and indolent forms of invasive carcinomas such as…”
Get full text

Rate of radial scars by core biopsy and upgrading to malignancy or high-risk lesions before and after introduction of digital breast tomosynthesis by Phantana-angkool, April, Forster, Meghan R., Warren, Yancey E., Livasy, Chad A., Sobel, Amy H., Beasley, Lakesha M., Trufan, Sally J., Hadzikadic-Gusic, Lejla, Sarantou, Terry, Voci, Amy E., Sarma, Deba, White, Richard L.

“…Purpose Radial scars (RS) commonly present mammographically as architectural distortions, but these lesions may be associated with non-invasive and invasive…”
Get full text

Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites by Burgess, Earle F., Livasy, Chad A., Symanowski, James T., Matulay, Justin T., Grigg, Claud M., Clark, Peter E., Raghavan, Derek

“…Novel regimens targeting immune checkpoints and the cMET or HER2 pathways are under investigation in metastatic urothelial carcinoma (mUC) though co-expression…”
Get full text

Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy? by Pestana, Christine V., Livasy, Chad A., Donahue, Erin E., Neelands, Brittany, Tan, Antoinette R., Sarantou, Terry, Hadzikadic-Gusic, Lejla, White, Richard L.

“…Background The extent of residual disease after neoadjuvant chemotherapy (NAC) can be quantified by the Residual Cancer Burden (RCB), a prognostic tool used to…”
Get full text

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy by Miller, Katherine R., Patel, Jai N., Zhang, Qing, Norris, Eric J., Symanowski, James, Michener, Chad, Sehouli, Jalid, Braicu, Ioana, Destephanis, Darla D., Sutker, Ashley P., Jones, Wendell, Livasy, Chad A., Biscotti, Charles, Ganapathi, Ram N., Tait, David L., Ganapathi, Mahrukh K.

“…Aberrant homeobox (HOX) gene expression is reported in high-grade serous ovarian carcinoma (HGSOC), however, its prognostic significance remains unclear. HOX…”
Get full text

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma by Norris, Eric J, Zhang, Qing, Jones, Wendell D, DeStephanis, Darla, Sutker, Ashley P, Livasy, Chad A, Ganapathi, Ram N, Tait, David L, Ganapathi, Mahrukh K

“…High grade serous ovarian carcinoma (HGSC) without identifiable serous tubal intraepithelial carcinoma (STIC) within the fallopian tube (FT) occurs in…”
Get full text